Jalid Sehouli, MD, Charite Universitätsmedizin Berlin, Berlin, Germany, discusses the most recent updates in endometrial, cervical and ovarian cancers from ESMO 2023. Dr. Sehouli highlights milestone trials, such as the Phase III cx11/GOG-3047/KEYNOTE-A18 (NCT04221945) trial, exploring checkpoint inhibitors in early-stage cervical cancer, and the Phase III DUO-E (NCT04269200) study introducing PARP inhibition in combination with checkpoint inhibitors for endometrial cancer. These trials signify a significant shift towards more personalized treatments, even in primary and chemo-naive settings. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
